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Abstract: Introduction. Hyperhomocysteinemia is known to predispose to atherosclerosis and occurs more 
commonly in patients with systemic lupus erythematosus (SLE) than in the general population. It has been shown 
that elevated plasma total homocysteine (tHcy) results in protein N-homocysteinylation and production of 
autoantibodies against N-homocysteinylated (N-Hcy) proteins. Objectives. The aim of the study was to investigate 
whether anti-N-Hcy-albumin antibodies occur in patients with SLE and identify factors that determine these 
antibodies in such a population. Patients and methods. In 50 subjects with SLE and 50 age- and sex-matched 
healthy controls, we determined serum IgG antibodies to N-Hcy-albumin using an in-house enzyme linked 
immunosorbent assay. Results. Patients had higher plasma tHcy and C-reactive protein (CRP) than controls, while 
serum folate and witamin B12 were lower in patients. Levels of anti-N-Hcy-albumin were higher in patients with  
SLE than in controls (medians: 0.31; vs. 0.19; p <0.0001). In SLE patients, levels of anti- N-Hcy-albumin antibodies 
correlated with tHcy (r = 0.83; p <0.0001), CRP (r = 0.33; p = 0.02) and the duration of the disease (r = 0.3;  
p = 0.04). Seropositivity to anti-N-Hcy-albumin antibodies was more frequent in SLE patients than in controls  
(50% vs 10%; p <0.001). In SLE patients tHcy and CRP concentrations, along with the duration of the disease, 
were independent predictors of anti-N-Hcy-albumin antibodies levels. There were no associations between a type 
or levels of antinuclear antibodies or patient’s age with anti-N-Hcy-albumin antibodies. Conclusions. Compared 
with healthy controls, in SLE patients levels of anti-N-Hcy-albumin antibodies are significantly higher and are 
largely determined by tHcy, CRP and the disease duration. This novel autoimmune response might contribute to an 
increased risk of vascular events in SLE patients.
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INTRODUCTION
Hyperhomocysteinemia has been reported an independent 
risk factor for coronary artery disease, cerebral infarction and 
peripheral arterial disease [1-5]. In patients with systemic lu-
pus erythematosus. (SLE), ischemic heart disease and stroke 
are associated with higher total plasma homocysteine (tHcy) 
levels compared to those without cardiovascular disease [6,7]. 
It has been published that in patients with SLE, hyperhomocy-
steinemia is associated with an increased risk of cardiac valve 
abnormalities [8] and the development of atherosclerotic pla-
ques in coronary arteries [7]. Moreover, elevated tHcy may be 
a marker of increased vascular risk in SLE patients with low 
levels of antiphospholipid antibodies [9]. Despite much exper-
imental work on Hcy role in cardiovascular diseases, mecha-
nisms by which Hcy is involved in the pathogenesis of vascular 
disease remain unclear.
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It has been reported that elevated Hcy levels causes: en-
dothelial cell dysfunction, cytotoxic effects, impaired fibri-
nolysis, enhanced vascular oxidative stress, vascular smooth 
muscle hypertrophy and increase in collagen synthesis in the 
vascular wall [10-12]. One of mechanisms for vascular injury 
induced by hyperhomocysteinemia might be a metabolic con-
version of Hcy to cyclic thioester, Hcy-thiolactone, catalyzed 
by menthionyl-t-RNA synthase [13] (fig. 1). Hcy-thiolactone, 
like other thioesters, is a highly reactive compound which 
acylates nucleophil groups e.g. the NH2 group. It has been 
documented that Hcy thiolactone reacts with proteins and 
forms amide bonds with amino groups of lysine residues [14]. 
This results in the generation of N-homocysteinylated protei-
ns (N-Hcy proteins), which can be detected in human serum 
[13,15]. Protein N-homocysteinylation rates are proportional 
to their lysine contents [14]. Albumin constitutes the major 
pool of plasma N-Hcy-proteins. N-homocysteinylation of ε-
amino groups of lysine residues results in the loss of positive 
charges and the SH group formation. In consequence, such N-
Hcy proteins lose their structure and biochemical properties 
(e.g. catalytic functions), and also they become susceptible to 
further oxidation. Non-enzymatic protein modification could 
be observed with as little as 10 nM thiolactone and N-ho-
mocysteinylation degree increases with the Hcy thiolactone 
concentration. N-Hcy proteins, such as albumin, can be re-
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azathioprine treatment was also allowed if discontinued wit-
hin at least 3 months preceding the onset of the study. Age, 
sex-matched apparently healthy individuals, free of any signs 
or symptoms, with normal results of routine laboratory blood 
tests, served as controls.
Blood samples were collected after a 14-hour overnight 
fast. Complete blood counts, creatinine and glucose concen-
trations, lipid profile, anti-nuclear antibody titers, anticar-
diolipin antibodies, lupus antycoagulant (LA), folic acid and 
vitamin B12 , methylenotetrahydrofolate reductase (MTHFR) 
C677T polymorphism and anti-N-Hcy albumin IgG antibody 
levels were determined. Plasma tHcy levels were determined 
by high-performance liquid chromatography (HPLC). High 
sensitivity CRP was measured by using latex nephelometry 
(Dade Behring). Titers and types of anti-nuclear antibody 
were assessed with indirect immunofluorescency by using the 
Hep-2010 cells. Anticardiolipin antibody levels were measu-
red by immunofluorescency according to a modified method 
by Harris et al. [23]. The LA presence was assessed in citrated 
plasma according to the three stage method recommended by 
Scientific and Standardization Committee of the Internatio-
nal Society on Thrombosis and Haemostasis [24]. Serum folic 
acid and vitamin B12 levels were measured using a Immunolite 
analyzer (Diagnostic Products Corp.) Serum levels of IgG anti-
bodies against N-Hcy-albumin were determined using an in-
house enzyme-linked immunosorbent assay; this method was 
developed in the Department of Molecular Genetics in New 
Jersey Medical School in Newark and modified in the Depart-
ment of Medicine Jagiellonian University School of Medicine 
in Cracow [17-19]. The MTHFR C677T polymorphism was 
determined by the polymerase chain reaction [25].
Statistical analysis
Normally distributed data are given as mean (x) ± stan-
dard deviation (SD). Variables, which were not normally distri-
buted are presented as median and interquartile range. Inter-
group differences were assessed using t-test for continuous 
variables with normal distribution and Mann-Whitney test for 
continuous not normally distributed data. Categorical variab-
les were analyzed by chi2 test. Correlation between continuous 
variables were assessed using Pearson’s test for normally distri-
buted data or Spearman test for remaining variables, respecti-
vely. Multiple linear regression analysis was used to determi-
ne independent factors which influence anti-N-Hcy-albumin 
antibody levels. A p-value below 0.05 was considered to be 
statistically significant.
RESULTS
The characteristics of patients and controls group are 
shown in the table 1. In the patient group a mean disease du-
ration was 10 years (9.9 ±5.5 years). Proteinuria (>0.5 g/24 h) 








Fig. 1. Homocysteine thiolactone synthesis
cognized as antigens and might activate humoral response of 
the immune system. Anti-N-Hcy protein IgG antibodies have 
been detected in humans [17-19]. Significant differences in le-
vels of anti-N-Hcy protein antibodies were found between yo-
ung male patients (<50 years old) with ischemic heart disease 
and healthy subjects [17]. It is worth noting that higher levels 
of anti-N-Hcy-protein antibodies were observed in patients 
with coronary artery disease compared with age, sex-matched 
controls even if there was no differences in plasma tHcy con-
centrations between these groups. [20]. Anti-N-Hcy-protein 
IgG antibodies have been also detected in patients after stroke 
[17] and in subjects with end-stage renal disease treated with 
hemodialysis [19]. Immunological consequences of hyperho-
mocysteinemia might be of importance in our understanding 
of a pathological Hcy influence on the vascular system. It is 
not known whether there is a tendency to produce anti-N-Hcy 
protein antibodies in patients with SLE. If so, whether these 
antibodies might contribute to the development of atheroscle-
rosis in patients with SLE. [21,22]. 
The aim of our study was to assess the occurrence of anti-
N-Hcy-albumin antibodies in patients with SLE compared to 
healthy controls. We also sought to determine factors which 
may determine the antibody levels in subjects with SLE.
PATIENTS AND METHODS
We enrolled 50 patients with SLE (diagnosis in accordance 
with the American Collage of Rheumatology revised criteria 
for the classification of SLE), aged between 18 and 60 years, 
to this case-control study. Patient were recruited in a stable 
phase of SLE. Exclusion criteria were symptoms of acute in-
fection, cancer, diabetes (fasting plasma glucose >7 mmol/L, 
measured twice), chronic renal disease (serum creatinine ≥177 
umol/L), coronary artery disease, acute or previous deep vein 
thrombosis or pulmonary embolism, pregnancy, liver insuf-
ficiency, hypo-or hyperthyroidism, treatment with drugs or 
vitamins known to affect tHcy concentration (e.g metotrexate, 
folic acid). Patients were allowed to take chloroquine, aspirin, 
statins, inhibitors of angiotensin converting enzyme (ACE-in-
hibitors), glucocorticosteroids. Previous cyclophosphamide and 
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which fulfilled the criteria of SLE, were found in 11 (22 %) 
patients and hematologic abnormalities (leucopenia, thrombo-
cytopenia) were observed in 19 patients (38%). The SLE-like 
syndrome, which is characterized mainly by skin changes and 
joints involvement, was observed in 8 patients (16%). Signifi-
cant titers of anti-nuclear antibodies were detected in all pa-
tients. Anti-double-stranded DNA antibodies were detected in 
17 patients (34%), anti-Ro antibodies in 20 (40%) and anti-La 
in 15 patients (30%). Moreover, 11 patients had anti-RNP an-
tibodies and 2 patients had anti-Sm antibodies. Antiphospho-
lipid syndrome was diagnosed in 3 (6%) patients (diagnosis 
according to the current criteria [27,28]). In 3 other patients 
elevated levels of anticardiolipin or anti-β2 glicoprotein I were 
found, while LA was detected in 10 (20%) patients. Treatment 
profile was as follows: 20% of patients (10 from 50) did not 
take any treatment at the time of enrollment in the study, 74 
% of patients (37 out of 50) were treated with oral glucocorti-
costeroids, 24% (12 out of 50) took chloroquine, 22% (11 out 
of 50 ) ACE inhibitor, 4% (2 out of 50) statins, 50% (25 out of 
50) cyclophosphamide or azathioprine in the past.
The SLE patients had higher tHcy and CRP concentra-
tions and lower folate, vitamin B12 and serum complement 
(C4) levels (tab. 1). Hyperhomocysteinemia, defined as tHcy 
concentration >15 μM/L, was found in 20% in SLE patients 
and in 2% in the control group 
(p <0.0001). The prevalence of the particular types of 
MTHFR C677T polymorphism did not significantly differ be-
tween patients and controls group (tab. 1).
In the patient group levels of anti-N-Hcy-albumin an-
tibody were significantly higher as compared to the control 
group (median, interquartile range: 0.31; 0.23–0.39 vs. 0.19; 
0.16–0.23; p <0.0001). 
Sex, age and creatinine concentration showed no associa-
tion with levels of anti-N-Hcy-albumin antibodies in either 
group. As expected, in SLE patients there was a significant 
positive correlation between tHcy and anti-N-Hcy-albumin 
Table 1.
Patients (n = 50) Controls (n = 50) p
Age (years) 42 (34–46) 42.2 (35–48) NS
Women/Men, n/n 45/5 45/5 NS
Haemoglobin (g/dl) 13.4 (12.6–13.7) 13.6 ±1.5 NS
RBC (x 106/ml) 4.4 ((4.13–4.72) 4.5 ±0.4 NS
WBC (x 103/ml) 4.85 (3.7–5.7) 5.2 (4.5–6) NS
Platelets (x 103/ml) 218.5 ±81.9 235.1 ±52.9 NS
Creatinine (μmol/l) 73.1 ±11.8 72.1 ±12.3 NS
C4  (g/l) 0.128 (082–0.173) 0.227 (0.175–0.26) <0.0001
Total cholesterol (mmol/l) 4.55 (4–5.2) 5 (4.4–5.8) 0.05
LDL cholesterol (mmol/l) 2.7 ±1.1 2.9 ±1 NS
HDL cholesterol (mmol/l) 1.4 ±0.3 1.6 ±0.4 0.01
Triglycerides (mmol/l) 1.23 (0.87–1.48) 0.91 (0.73–1.52) NS
Glucose (mmol/l) 4.67 ±0.6 4.95 ±0.5 0.01
C-reactive protein (mg/l) 2.29 (0.8–4.81) 0.79 (0.26–1.44) 0.0002
Folic acid (nmol/l) 5.13 (3.99–6.35) 9.18 (6.99–11.1) <0.0001
Vitamin B12 (pg/ml) 241 (203–290) 313.5 (248–402.5) 0.001
C677T MTHFR CC n (%) 26 (52%) 26 (52%) NS
C677T MTHFR CT n (%) 20 (40%) 19 (38%) NS
C677T MTHFR TT n (%) 4 (8%) 5 (10%) NS
Homocysteine (μmol/l) 11.45 (9.2–13.6) 8.93 (8.1–10.4) 0.0002
Homocysteine >15 μmol/l n (%) 10 (20) 1 (2) p <0.0001
Anti-N-Hcy-albumin IgG antibodies (A490) 0.31 (0.23–0.39) 0.19 (0.16–0.23) <0.0001
Seropositivity status n (%) 25 (50) 5 (10) p <0.001
Normally distributed data are presented as mean ± standard deviation (x ±SD), remaining continuous data are presented as median and 
interquartile interval. Abbreviations: C4 – complement, HDL – high density lipoprotein, LDL – low density lipoprotein, MTHFR – 
methylenotetrahydrofolate reductase, NS – non-significant, RBC – red blood count, WBC – white blood count. Seropositivity status denotes 
anti-N-Hcy-albumin IgG antibodies level over 90th percentile in controls
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antibodies (r = 0.83; p <0.0001; fig. 2A). However, there was 
no association between folic acid or vitamin B12  and these an-
tibodies. Interestingly, in SLE patients we observed weak posi-
tive correlations between anti-N-Hcy-albumin antibodies and 
CRP concentration (r = 0.33; p = 0.02) and disease duration 
(r = 0.3; p = 0.04). There were no associations between anti-
N-Hcy-albumin antibodies and others autoantibodies (anti-
cardiolipin, anti-β2 glicoprotein I and antinuclear antibodies). 
We only found significantly higher levels of anti-N-Hcy-albu-
min antibody in patients with LA compared to the remaining 
SLE patients (median, interquartile range: 0.41; 0.34–0.51 vs. 
0.26; 0.22–0.36; p = 0.02). There was no significant associa-
tion between MTHFR C677T genotype and anti-N-Hcy-al-
bumin antibodies levels.
In the control group anti-N-Hcy-albumin antibodies cor-
related only with tHcy concentration (r = 0.5; p = 0.002; fig. 
2B).
Seropositivity, which was defined as the ELISA reading 
above the value corresponding to the 90th percentile of the 
control group, i.e. 0.3055 (tab. 1), was 5-fold more frequent in 
patients than in controls (p <0.001). Multiple linear regres-
sion analysis showed that tHcy concentration, SLE presence 
and CRP concentration were independent predictors of anti-
N-Hcy-albumin antibody levels in both groups (tab. 2). Si-
milarly, in SLE patients tHcy concentration, disease duration 
and CRP concentration independently predicted levels of these 
antibodies (data not shown).
DISCUSSION
The present study is the first to demonstrate that in SLE 
patients there is a tendency to form anti-N-Hcy-albumin 
IgG antibodies and levels of these antibodies are significantly 
higher than in healthy individuals matched for age and sex. 
In line with previous observations, we found markedly higher 
tHcy concentrations in patients with SLE than in the control 
group. Levels of vitamins (folic acid and vitamin B12), which 
are involved in Hcy metabolism, were also lower in patients 
with SLE. A positive correlation between tHcy concentration 
and anti-N-Hcy-albumin antibodies level was confirmed in 
SLE patients and controls, however in patients with SLE the 
correlation was stronger than in the healthy group, which cor-
roborates previous findings in patients with coronary artery 
disease [20]. However, in the latter study by Undas A et al. 
[20], subjects with coronary disease had higher tHcy plasma 
concentrations than SLE patients presented in this study (mean 
concentration 20.0 vs. 12.5 umol/l, respectively). Therefore, it 
might be speculated that a correlation value, which we found 
in our patient group, does not only result from higher tHcy 
levels than in controls. Interestingly, in accordance with the 
previous observations in patients with coronary disease aged 
50 years or less [18], we found a weak, but significant, cor-
relation between anti-N-Hcy-albumin antibodies and CRP 
levels in SLE patients. Although the association of plasma 
tHcy concentration and CRP levels has not been reported so 
far, links between hyperhomocysteinemia and inflammation 
might be of importance. This hypothesis might be supported 
by the phenomenon of Hcy participation in recruitment of le-
ucocytes to the site of vascular injury described by Poddar et 
al. [29] and activation of the immune system, associated with 
increased production of reactive oxygen species and enhan-
ced requirements of vitamins, which deficiencies result in an 
increase in tHcy concentration [30,31]. Our findings, presen-
ted in the current study, suggest that pathological activation 
of the immune system in patients with SLE and enhanced pro-
inflammatory cytokine production, leading to increased levels 
of inflammatory markers (e.g. CRP), might have been also as-
sociated with undue response to N-Hcy-proteins. One might 
put forward a hypothesis that increased production of anti-N-
Hcy-protein antibodies, like it occurs against other antigens, 
is associated with inflammation at the site of injured vascular 
Fig. 2A. Association between plasma total homocysteine (tHcy) concentrations and anti-N-homocysteinylated-albumin antibody levels in 
patients group. B. Association between plasma total homocysteine (tHcy) concentrations and anti-N-homocysteinylated-albumin antibody 
levels in controls group
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wall and it may explain one of the pathological mechanisms of 
premature atherosclerosis in patients with SLE.
In our study we also observed that levels of anti-N-Hcy-
albumin antibodies positively correlate with the duration of 
clinically overt SLE. Moreover, using multiple linear regres-
sion analyses, we found the disease duration as an independent 
predictor of levels of the antibodies studied. It is worth empha-
sizing that disease duration is one of independent risk factors 
of coronary artery calcification [7] and atherosclerotic plaque 
in extracranial carotid arteries [33]. The correlation, which we 
observed, might be another argument to support the concept 
of involvement of anti-N-Hcy-albumin antibodies in the pat-
hogenesis of atherosclerosis.
Interestingly, we found no association between anti-N-
Hcy-albumin antibodies and antinuclear antibody titers nor 
types, anti-double stranded DNA antibodies also did not cor-
relate with these antibodies aginst homocysteinylated prote-
ins. However, the presence of SLE was an independent pre-
dictor of anti-N-Hcy-albumin antibody levels in regression 
analyses. This observation might be explained by lack of di-
rect clinical association between anti-nuclear antibodies titers 
and SLE activity or progression. We also did not observe the 
association between antiphospholipid or anti-β2-glicoprotein 
I antibodies and anti-N-Hcy-albumin antibodies. We sho-
uld also remember that patients with an acute or past venous 
or arterial thrombosis were excluded from our study because 
these conditions are associated with hyperhomocysteinaemia. 
According to this assumption we found only 3 (6%) cases of 
antiphospolipid syndrome, diagnosed according to the current 
clinical and laboratory criteria, while in other 3 patients we de-
termined elevated levels of antiphospholipid or anti-β2-glico-
protein I IgG antibodies and this class of antibodies seems to 
be associated with anti-N-Hcy-albumin antibodies (unpublis-
hed data). However, we observed a significantly elevated level 
of anti-N-Hcy-albumin antibodies in LA positive patients.
In conclusion SLE patients in a stable phase of disease have 
significantly higher anti-N-Hcy-albumin IgG antibodies le-
vels than healthy individuals. Total Hcy concentration, CRP 
level and disease duration are independent predictors of levels 
of these antibodies. These preliminary observations expand 
the current knowledge about autoantibodies which are pro-
duced in SLE and may affect the clinical presentation of this 
disease. It is not known how treatment with folic acid, which 
reduces tHcy levels, may influence the disease course. Further 
studies on role of autoimmunologic reactions associated with 
hyperhomocysteinaemia in SLE are necessary.
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